Osocimab
Osocimab (BAY 1213790), an anti-FXIa antibody (Ki=2.4 nM; EC50=0.2 nM) . FXI inhibition may reduce the risk of thrombosis. Osocimab inhibits thrombin generation, and prolongs activated partial thromboplastin time. Osocimab exhibits anticoagulant effects[1].
Product Specifications
CAS Number
2056878-75-0
Product Name Alternative
BAY 1213790
UNSPSC
12352203
Target
Factor Xa
Type
Inhibitory Antibodies
Related Pathways
Metabolic Enzyme/Protease
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/osocimab.html
Purity
98.00
Solubility
10 mM in DMSO
Smiles
[Osocimab]
Molecular Weight
(145.5 kDa)
References & Citations
[1]Schaefer M, et al. Allosteric Inhibition as a New Mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated Form of Coagulation Factor XI. J Mol Biol. 2019 Dec 6;431 (24) :4817-4833.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
K0730704 1.0 µg DNA
FAM75A2 sgRNA CRISPR Lentivector (Human) (Target 3)
Sign In for Pricing
View Details 